Communiqués Interpace Biosciences, Inc.

Actions

IDXG

US46062X3035

Installations et services en soins de santé

Temps réel OTC Markets Autres places de cotation 21:36:59 04/06/2026			Varia. 5j.	Varia. 1 janv.
1,790 ^USD	+2,29%		+23,45%	+45,50%

12/05	Interpace Biosciences, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI
30/03	Interpace Biosciences, Inc. publie ses résultats pour le quatrième trimestre clos le 31 décembre 2025	CI

Communiqués

12/05	Interpace Biosciences Announces First Quarter 2026 Financial and Business Results	AQ
30/03	Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results	AQ
20/01	Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Revenue Guidance and Simplification of Capital Structure	AQ
03/12	Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners	AQ
12/11	Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results	AQ
16/09/25	Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association Annual Meeting	AQ
15/09/25	Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting	AQ
07/08/25	Interpace Biosciences Announces Second Quarter 2025 Financial and Business Results	AQ
08/05/25	Interpace Biosciences Announces First Quarter 2025 Financial and Business Results	AQ
24/04/25	Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk	AQ
03/02/25	Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results	AQ
31/01/25	Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results	AQ
27/01/25	PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan	AQ
10/01/25	Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk	AQ
06/11/24	Interpace Biosciences : Announces Record Third Quarter 2024 Financial and Business Results Form 8 K	PU
04/11/24	Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results	AQ
15/10/24	Interpace Biosciences : Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to Nasdaq Form 8 K	PU
15/10/24	Interpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to Nasdaq	AQ
01/08/24	Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results	AQ
30/07/24	Interpace Diagnostics Announces Undefined Extension of Medicare Coverage for PancraGEN, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts	AQ
29/07/24	Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts	AQ
04/06/24	Interpace Diagnostics Announces New Data Analyzing Imbalance of Short Tandem Repeat Alleles for Pancreatic Cancer Detection Published as an ASCO 2024 Abstract	AQ
09/05/24	Interpace Biosciences Announces First Quarter 2024 Financial and Business Results	AQ
07/03/24	Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results	AQ
08/11/23	Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results	AQ